Pancolitis a novel early complication of Alemtuzumab for MS treatment

Mult Scler Relat Disord. 2016 May:7:83-4. doi: 10.1016/j.msard.2016.03.014. Epub 2016 Mar 30.

Abstract

The growing range of effective therapies for relapsing remitting multiple sclerosis (RRMS) brings with it a wider range of possible complications requiring broader considerations and greater vigilance. Alemtuzumab is a humanized monoclonal antibody against CD52 that is highly effective in the treatment of RRMS and approved in many countries around the world. We describe a case presenting with a complication not previously seen.

Keywords: Alemtuzumab; Complications; Infections; Multiple sclerosis.

Publication types

  • Case Reports

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Colitis / complications*
  • Colitis / drug therapy
  • Humans
  • Immunologic Factors / adverse effects*
  • Immunologic Factors / therapeutic use
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / complications*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunologic Factors
  • Alemtuzumab